Tier 2 — strong

Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults

Lynn Cialdella-Kam, David C Nieman, Wei Sha, Mary Pat Meaney, Amy M Knab, R Andrew Shanely
The British journal of nutrition 2013 109(11):1923

Bibliography

PubMed
PMID 23151341
DOI
10.1017/S0007114512003972
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled metabolomics study
ModelHuman intervention research
Sample100 adults aged 40–83 years
InterventionQuercetin 500 or 1,000 mg/day combined with vitamin C and niacin, or placebo
Duration3 months
EndpointsInflammatory measures; Oxidative-stress measures; Exposure and pharmacokinetics

What the study showed, in plain terms

Published in 2013, this source examined forms, absorption and food sources. Design: Randomized double-blind placebo-controlled metabolomics study. Sample/model: 100 adults aged 40–83 years. The exposure or intervention was Quercetin 500 or 1,000 mg/day combined with vitamin C and niacin, or placebo. Follow-up or treatment period: 3 months.

Supplementation altered circulating quercetin conjugates and selected metabolite profiles, particularly at the higher dose; inflammatory and oxidative metabolite measures were not improved.

Multi-ingredient exploratory biomarker analysis. Metabolite shifts do not establish clinical benefit; related community-trial reports may share participants.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Supplementation altered circulating quercetin conjugates and selected metabolite profiles, particularly at the higher dose; inflammatory and oxidative metabolite measures were not improved.
  • The recorded outcome domains were Inflammatory measures; Oxidative-stress measures; Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 500 or 1,000 mg/day combined with vitamin C and niacin, or placebo; 3 months.

What this study can and cannot tell us

  • Multi-ingredient exploratory biomarker analysis. Metabolite shifts do not establish clinical benefit; related community-trial reports may share participants.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Influence of quercetin supplementation on disease risk factors in community-dwelling adults
Amy M Knab et al. · Journal of the American Dietetic Association · 2011
Tier 2
Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial
Serena A Heinz et al. · Pharmacological research · 2010
Tier 2
The variable plasma quercetin response to 12-week quercetin supplementation in humans
F Jin et al. · European journal of clinical nutrition · 2010
Tier 2
Quercetin with vitamin C and niacin does not affect body mass or composition
Amy M Knab et al. · Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2011
Tier 2
The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial
Joshua J Broman-Fulks et al. · Therapeutic advances in psychopharmacology · 2012
Tier 2
A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects
Serena A Heinz et al. · The British journal of nutrition · 2010

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology